TW200640948A - DR5 antibodies and uses thereof - Google Patents
DR5 antibodies and uses thereofInfo
- Publication number
- TW200640948A TW200640948A TW095103829A TW95103829A TW200640948A TW 200640948 A TW200640948 A TW 200640948A TW 095103829 A TW095103829 A TW 095103829A TW 95103829 A TW95103829 A TW 95103829A TW 200640948 A TW200640948 A TW 200640948A
- Authority
- TW
- Taiwan
- Prior art keywords
- antibodies
- cancer
- compositions
- treatment
- making
- Prior art date
Links
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention concerns anti-DR5 antibodies with improved properties, compositions comprising such antibodies, methods and means for making such antibodies, and their therapeutic use, in particular in the treatment of cancer.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US64955005P | 2005-02-02 | 2005-02-02 |
Publications (2)
Publication Number | Publication Date |
---|---|
TW200640948A true TW200640948A (en) | 2006-12-01 |
TWI419903B TWI419903B (en) | 2013-12-21 |
Family
ID=37820467
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW95103829A TWI419903B (en) | 2005-02-02 | 2006-02-03 | Dr5 antibodies and uses thereof |
Country Status (4)
Country | Link |
---|---|
AR (1) | AR052109A1 (en) |
MY (1) | MY160566A (en) |
TW (1) | TWI419903B (en) |
ZA (1) | ZA200706246B (en) |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2287911C (en) * | 1997-05-15 | 2014-05-06 | Genentech, Inc. | Apo-2 receptor |
-
2006
- 2006-01-31 ZA ZA200706246A patent/ZA200706246B/en unknown
- 2006-02-02 AR ARP060100379 patent/AR052109A1/en active IP Right Grant
- 2006-02-03 MY MYPI20060477A patent/MY160566A/en unknown
- 2006-02-03 TW TW95103829A patent/TWI419903B/en active
Also Published As
Publication number | Publication date |
---|---|
ZA200706246B (en) | 2008-11-26 |
TWI419903B (en) | 2013-12-21 |
MY160566A (en) | 2017-03-15 |
AR052109A1 (en) | 2007-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1109638A1 (en) | Dr5 antibodies and uses thereof dr5 | |
IL258880A (en) | Diarylhydantoin compounds | |
IL244803A0 (en) | Humanized anti-beta7 antibodies and uses therefore | |
WO2007053573A3 (en) | Treatment of cancer with sorafenib | |
WO2007061874A3 (en) | Methods and compositions for use in treating cancer | |
MX2007011545A (en) | Combinations for the treatment of cancer comprising anti-egfr antibody and vegfr inhibitors. | |
MX2009006466A (en) | Methods of treatment. | |
IL190796A0 (en) | Compositions and their uses for gene therapy of bone conditions | |
SG164368A1 (en) | Treatment of cancer | |
WO2006113483A3 (en) | Methods and compositions for treating or preventing cancer | |
MX2009008430A (en) | Anti-robo4 antibodies and uses therefor. | |
IL214325A (en) | Anti-cmet antibody, composition comprising it and use thereof | |
MXPA06014510A (en) | Compositions and methods for treating inflammatory disorders. | |
WO2007064872A3 (en) | Urea compounds useful in the treatment of cancer | |
WO2008124660A3 (en) | Methods and compositions for the treatment of cancer | |
SG160412A1 (en) | Anti-igfr1 antibody therapeutic combinations | |
NZ599875A (en) | Human il-23 antigen binding proteins | |
MX2009008347A (en) | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use. | |
JO2795B1 (en) | Immunoglobulines | |
NZ579478A (en) | Epha3 antibodies for the treatment of solid tumors | |
TW200716088A (en) | Formulations and methods for treating amyloidosis | |
UA99601C2 (en) | Use of an anti-cd151 antibody in the treatment of cancer | |
MX2009010269A (en) | Methods of treating cancer by administering human il-18 combinations. | |
DE602005015329D1 (en) | RUTHENIUM COMPOSITIONS FOR CANCER TREATMENT | |
TW200640948A (en) | DR5 antibodies and uses thereof |